Biocytogen and Nanjing Chia Tai Tianqing Announce IND Approval in China for Co-Developed Anti-IGF-1R Antibody NTB003 (BCG009)




Biocytogen and Nanjing Chia Tai Tianqing Announce IND Approval in China for Co-Developed Anti-IGF-1R Antibody NTB003 (BCG009)

BEIJING & NANJING, China–(BUSINESS WIRE)–Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) and Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. (“NJCTTQ”) announced that NTB003 (formerly BCG009), a co-developed injectable drug candidate, has received the Investigational New Drug (IND) approval from the National Medical Products Administration (NMPA). The approved indication is Thyroid Eye Disease (TED).

About NTB003 Injection

NTB003 is a second-generation fully human anti-IGF-1R monoclonal antibody co-developed by Biocytogen and Nanjing Chia Tai Tianqing. Antibody discovery and optimization were completed by Biocytogen using its proprietary RenMab™ fully human antibody discovery platform, while Nanjing Chia Tai Tianqing was responsible for CMC process development, GLP-compliant toxicology studies, and IND application. Compared with first-generation approved anti-IGF-1R therapeutics, NTB003 demonstrates enhanced molecular affinity, improved druggability, and an extended half-life. In vitro studies have shown that NTB003 exerts potent signal-blocking activity and effectively inhibits the release of hyaluronic acid (HA), indicating strong potential for further clinical development.

Clinical studies of teprotumumab and other investigational anti-IGF-1R biologics have demonstrated that targeting IGF-1R can deliver significant clinical benefits. These agents have shown rapid onset of therapeutic response and favorable outcomes in reducing proptosis and diplopia, improving quality of life, and lowering clinical activity scores in patients with TED.

Nanjing Chia Tai Tianqing will lead the clinical development and commercialization of NTB003 in China, aiming to provide an improved therapeutic option for Chinese TED patients. Biocytogen will be responsible for the global out-licensing of the product outside China.

About Biocytogen

Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice^® (RenMab^™/ RenLite^®/ RenNano^®/ RenTCR-mimic™ ) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of December 31, 2024, approximately 200 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice^® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company’s sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit http://en.biocytogen.com.cn.

Contacts

Biocytogen Contacts
Antibody assets and platforms: BD-Licensing@biocytogen.com
Media: pr@bbctg.com.cn

Inter Scientific Achieves UK GLP Monitoring Authority Status to Support Regulatory Studies for Medicines, Devices and Novel Products




Inter Scientific Achieves UK GLP Monitoring Authority Status to Support Regulatory Studies for Medicines, Devices and Novel Products

LIVERPOOL, England–(BUSINESS WIRE)–#InterScientific–Inter Scientific Ltd is proud to announce its acceptance onto the UK Good Laboratory Practice (GLP) Monitoring Authority, granting the company official GLP status. This accreditation enables Inter Scientific to conduct fully compliant non-clinical safety studies in accordance with OECD guidelines and GLP standards, supporting the authorisation of regulated products such as pharmaceuticals, medical devices, cosmetics, and products requiring Premarket Tobacco Product Applications (PMTAs).

The GLP status is a major milestone for Inter Scientific and reflects the company’s commitment to delivering the highest standards of scientific and regulatory excellence. It enhances the company’s ability to provide accurate, defensible data for regulatory submissions in the UK and internationally.

“This is a significant step forward for Inter Scientific,” said David Lawson, CEO of Inter Scientific. “Achieving GLP status recognises the quality of our people, systems, and scientific capabilities. It allows us to support clients more comprehensively in bringing safe, effective, and compliant products to market.”

The GLP framework ensures the reliability, integrity, and traceability of data submitted to regulatory bodies. Inter Scientific’s accreditation confirms its laboratories meet the rigorous requirements set out by the UK GLP Monitoring Authority.

Ben Green, Global Technical Specialist for Nicotine-Containing Products at Inter Scientific, added: “Our focus has always been on delivering accurate, impartial regulatory studies that ultimately support public health. GLP accreditation underlines our readiness to contribute to the responsible regulation of a wide range of consumer and healthcare products.”

Inter Scientific’s inclusion on the official UK GLP Compliance Monitoring Programme can be found here: https://assets.publishing.service.gov.uk/media/67c6d137b0bb6528ee866d94/Current-Members_of_the_UK_GLP_Compliance_monitoring_Programme_Version_15.pdf

About Inter Scientific Ltd

Inter Scientific is a regulatory science company specialising in global regulatory compliance and providing laboratory testing and consultancy for medicines, medical devices, cosmetics, and novel nicotine products. With a multidisciplinary team of experts, the company supports clients globally through all stages of product development and regulatory submission.

Contacts

Email: razieh.alipour@inter-scientific.com

Applied Cognition Publishes First-in-Human Study of Glymphatic Function in Nature Biomedical Engineering




Applied Cognition Publishes First-in-Human Study of Glymphatic Function in Nature Biomedical Engineering

Breakthrough enables continuous, non-invasive monitoring of the brain’s waste clearance system, unlocking new drug targets for Alzheimer’s and other neurodegenerative diseases

SAN FRANCISCO–(BUSINESS WIRE)–Applied Cognition, a clinical-stage platform therapeutic company, today announced the publication of a groundbreaking study in Nature Biomedical Engineering demonstrating the first continuous, non-invasive measurement of human glymphatic function—the brain’s system for clearing waste, including Alzheimer’s-associated proteins like amyloid and tau.

Working with researchers at the University of Florida and the University of Washington School of Medicine, the company validated its novel multimodal electrical impedance spectroscopy device using contrast-enhanced MRI. The platform also revealed, for the first time in humans, how EEG and cardiovascular physiology contribute to sleep-active glymphatic activity.

“This work is pivotal in defining the role glymphatic dysfunction plays in Alzheimer’s and discovering therapies to rescue it,” said Dr. Paul Dagum, CEO and co-founder of Applied Cognition. “Our platform has already identified a promising drug candidate that improves glymphatic clearance in early clinical trials.”

Originally characterized in rodents, the glymphatic system plays a vital role in the removal of toxic proteins. Until now, studying its function in humans has been limited to slow, high-cost MRI scans. Applied Cognition’s technology offers a scalable solution that allows real-time, remote, and high-resolution tracking, enabling new avenues for drug discovery.

Co-author on this study was Dr. Jeffrey Iliff, PhD, Psychiatry, University of Washington School of Medicine, who along with Dr. Maiken Nedergaard at the University of Rochester Medical Center characterized the glymphatic system in rodents.

“This unlocks our ability to study glymphatic function in the real world and with high-temporal resolution, not just the MRI suite, giving us new mechanistic insights of its role in neurological and psychiatric conditions,” said Dr. Iliff.

Piyush Jain, Head of New Products at Genentech, added: “Applied Cognition is bridging the gap between lab science and patient care. Their platform is accelerating the discovery of drugs that target the clearance of misfolded proteins at the root of devastating neurological diseases.”

Applied Cognition is advancing its lead drug program for early-stage Alzheimer’s and expanding its pipeline across neurodegenerative and psychiatric disorders.

The paper’s authors include Paul Dagum, Laurent Giovangrandi, Swati Rane Levendovszky, Jake J. Winebaum, Tarandeep Singh, Yeilim Cho, Robert M. Kaplan, Michael S. Jaffee, Miranda M. Lim, Carla Vandeweerd, and Jeffrey J. Iliff.

For the full report, click here. To learn more, visit: www.appliedcognition.com

About Applied Cognition

Applied Cognition is clinical-stage platform therapeutics company advancing the brain’s glymphatic system to drug development. Enhancing glymphatic function is a promising new therapeutic strategy for treating neurodegenerative diseases. Using its first-in-class platform, which enables continuous monitoring of glymphatic activity in humans, the company has successfully identified the first therapeutic target and lead drug candidate to enhance glymphatic clearance of amyloid and tau. Applied Cognition is currently advancing this lead program for early-stage Alzheimer’s and expanding its pipeline to explore treatments for other conditions using its platform.

Contacts

kaylaa@vsc.co

3D Investment Partners Recommends Toho Holdings Shareholders Vote Against the Reappointment of CEO Hiromi Edahiro, and Outside Director Yoshiaki Kamoya and Hidehito Kotani at the Company’s 77th Annual General Meeting




3D Investment Partners Recommends Toho Holdings Shareholders Vote Against the Reappointment of CEO Hiromi Edahiro, and Outside Director Yoshiaki Kamoya and Hidehito Kotani at the Company’s 77th Annual General Meeting

Repeated scandals, an attitude that is suspected as concealment and a lack of succession planning at Toho HD indicate its serious breakdown in corporate governance

The Board of Directors continues to reject reasonable proposals for operational improvement, obstructing the Company’s path to sustainable value creation

The persistent failure to address compliance issues risks alienating its customers and could lead to irreversible damage to corporate value

To resolve these problems, we strongly urge shareholders to vote against the reappointment of Mr. Hiromi Edahiro, Mr. Yoshiaki Kamoya and Mr. Hidehito Kotani at the upcoming Annual General Meeting

TOKYO–(BUSINESS WIRE)–3D Investment Partners Pte. Ltd., the investment manager of 3D Opportunity Master Fund (collectively referred to as “3D” or “we,” meaning either or both of 3D Investment Partners Pte. Ltd. and 3D OPPORTUNITY MASTER FUND), today released a shareholder presentation highlighting the ongoing and serious corporate governance failures at Toho Holdings Co., Ltd. (“Toho HD” or the “Company”) (TOKYO: 8129). The presentation outlines in detail the reasons why 3D recommends shareholders vote against the reappointment of Representative Director, President and CFO Hiromi Edahiro (“Mr. Edahiro”) and, Outside Director Yoshiaki Kamoya (“Mr. Kamoya”) and Hidehito Kotani (“Mr. Kotani”).

Link to presentation: https://www.3dipartners.com/engagement/toho-maximizing-corporate-value-en-202505.pdf

3D has been a shareholder of Toho HD since 2020 and currently holds approximately 22%¹ of the voting rights, making it one of the Company’s largest shareholders. Over the past two years, 3D has engaged in constructive dialogue with Toho HD with the sole aim of enhancing long-term corporate value.

¹ Calculated as: (Number of shares held by us + Number of potential shares from convertible bonds with stock acquisition rights held by us) ÷ (Total number of issued shares – Treasury shares + Number of potential shares from convertible bonds with stock acquisition rights held by us).

Management Issues at Toho HD

3D believes that the fundamental management challenges facing Toho HD—specifically, the low profitability of its core business and an inefficient balance sheet—stem from a serious deficiency in its corporate governance structure. In August 2023, we submitted concrete proposals to address these management issues to Toho HD, which were disclosed in our press release dated March 25, 2025. However, due to Toho HD’s dysfunctional governance, the Board of Directors was unable to objectively evaluate and implement recommendations which would improve the Company’s profitability and value. As a result, the majority of our proposals were dismissed, and the underlying issues remain unresolved.

As long as this governance failure persists, we believe that these management challenges will remain unresolved and long-term corporate value growth will continue to be impaired.

Repeated Scandals and Involvement in the Nihon University Incident

Toho HD has been subject to administrative sanctions for its involvement in bid-rigging on three separate occasions. Nevertheless, the Company has never conducted a thorough investigation of these scandals led by independent experts and has consistently avoided addressing the root causes of its misconduct.

In addition to the bid-rigging incidents, it has recently come to light that Toho HD was involved in a fraudulent scheme related to Nihon University Hospital (the “Nihon University Incident”). In this case, a part of funds that should have been returned from Toho HD as purchase rebates were instead funneled to third parties by the Company through fictitious consulting contracts, and resulting in the illicit payments. The Company was obviously able to notice that the scheme involved such clear compliance violations at the time of execution since another peer company reportedly refused to participate.

An attitude that is suspected as Concealment

Despite the seriousness of the Nihon University Incident, Toho HD has failed to provide any public explanation. Statements made by Mr. Edahiro during media interviews are in conflict with case records, raising serious concerns about the credibility and transparency of his explanations. Moreover, Toho HD has refused our request to establish a third-party investigative committee that is independent from the Company. Furthermore, during meetings we have had with the Company, senior executives (Shikkoyakuin) have asked us to refrain from further inquiries. This response, among others, can only be interpreted as attempts to conceal the truth.

Toho HD’s assertion that “There was no legal violation,” and the decision to take no further action, do not meet the standards of governance required for a listed company. What shareholders are demanding is not the mere absence of illegality, but the presence of sufficient transparency and a sound governance framework necessary for long-term corporate value creation.

Risks of Irreparable Damage to Corporate Value

The Board’s continued failure to address the Company’s compliance issues threatens to erode trust among business partners, potentially leading to revenue losses. This poses the risks of irreparable damage to corporate value. Based on its unwillingness to address these serious issues, we believe the Board of Directors is fundamentally unfit to enhance corporate value.

Our Recommendation Regarding Voting at the General Meeting

In light of the urgent need to rectify Toho HD’s governance failures, we strongly recommend that shareholders vote against the reappointment of Mr. Edahiro (Representative Director, President, and CFO), Mr. Kamoya and Mr. Kotani (Outside Directors) for the following reasons:

Regarding Mr. Edahiro:

• He was centrally involved in the management of the companies, which are Toho HD or its subsidiary involved in two prior bid-rigging scandals as well as the Nihon University Incident, and must be held accountable for the ongoing governance failures.
• His public statements have critically contradicted case records, raising serious concerns about the credibility and transparency of his explanations.
• He was appointed CEO without any external comparison or being held accountable for past scandals, through an internal succession process that lacks transparency.

Regarding Mr. Kamoya:

• Despite being the longest-serving outside director, he is not a member of the Special Committee on Governance Enhancement, reflecting a troubling indifference toward governance and compliance issues.
• Although he should have taken a central role in the Nomination Committee as a previous chairperson thereof, he did not even try to pursue the responsibilities for the past scandals and failed to fulfill his responsibilities of exercising proper oversight in selecting a qualified successor CEO. Furthermore, the internal CEO succession process lacked transparency and, to our knowledge, no attempt was made to look for and evaluate outside candidates.
• He currently serves as an advisor to a company with which Toho HD holds cross-shareholdings, casting significant doubt on his independence.

Regarding Mr. Kotani:

• As a member of the Nomination Committee, he was involved in last year’s process of appointing Mr. Edahiro as CEO.
• Furthermore, this year, regarding the decision to reappoint Mr. Edahiro as CEO, Mr. Kotani has not fulfilled his responsibilities as a chairperson of the Nomination Committee who should play the key role of the committee. The internal CEO succession process lacked transparency and, to our knowledge, no attempt was made to look for and evaluate outside candidates.

To Shareholders

As outlined above, we understand that Toho HD is suffering from a critical failure of governance, which in our view has led to the neglect of pressing management issues, the loss of growth opportunities, and significant risk of value destruction due to unresolved compliance concerns.

We respectfully urge shareholders to review our presentation and support the restoration of sound governance and sustainable long-term value creation at Toho HD by voting against the reappointment of Mr. Edahiro, Mr. Kamoya and Mr. Kotani at the Company’s upcoming Annual General Meeting.

About 3D Investment Partners Pte. Ltd.

3D Investment Partners Pte. Ltd. is an independent Singapore-based Japan focused value investing fund manager founded in 2015. 3D Investment Partners Pte. Ltd. focuses on partnering with management[s] who share its investment philosophy of medium- to long-term value creation through compound capital growth and a common objective of achieving long-term returns.

Disclaimer

This press release, including annexes is provided for informational purposes only and does not constitute an offer to purchase or sell any security or investment product, nor does it constitute professional or investment advice. This press release should not be relied on by any person for any purpose and is not, and should not be construed as investment, financial, legal, tax or other advice.

3D Investment Partners Pte. Ltd. and its affiliates and related persons (“3DIP”) of either believe that the current market price of Toho HD does not reflect its intrinsic value. 3DIP acquired beneficial and/or economic interests based on its own idea that Toho HD securities have been undervalued and provide an attractive investment opportunity and may in the future beneficially own, and/or have an economic interest in, Toho HD securities. 3DIP intends to review its investments in Toho HD on a continuing basis and, depending upon various factors including, without limitation, Toho HD’s financial position and strategic direction, the outcome of any discussions with Toho HD, overall market conditions, other investment opportunities available to 3DIP, and the availability of Toho HD securities at prices that would make the purchase or sale of Toho HD securities desirable, 3DIP may, from time to time (in the open market or in private transactions), buy, sell, cover, hedge, or otherwise change the form or substance of any of its investments (including the investment in Toho HD securities) to any degree in any manner permitted by any applicable law, and expressly disclaims any obligation to notify others of any such changes.

3DIP provides no representation or warranty, either expressed or implied, in relation to the accuracy, completeness, or reliability of the information contained herein (including content or quotes from news coverage or other third-party public sources (“Third-Party Materials”)), nor is it intended to be a complete statement or summary of the securities, markets, or developments referred to herein. 3DIP expressly disclaims any responsibility or liability for any loss whatsoever arising from any use of, or reliance on, this press release or its contents as a whole or in part by any person, or otherwise whatsoever arising in connection with this press release. 3DIP hereby expressly disclaims any obligation to update or provide additional information regarding the contents of this press release or to correct any inaccuracies in the information contained in this press release.

3DIP disclaims any intention or agreement to be treated as a joint holder (kyodo hoyu sha) under the Financial Instruments and Exchange Act of Japan, a closely related party (missetsu kankei sha) under the Foreign Exchange and Foreign Trade Act with other shareholders, or receiving any power or permission to represent other shareholders in relation to the exercise of their voting rights, and has no intention to solicit, encourage, induce or require any person to cause other shareholders to represent such voting rights.

3DIP does not have the intention to make a proposal, directly or through other shareholders of Toho HD, to transfer or abolish the business or assets of Toho HD and/or Toho HD group companies at the general shareholders meeting of Toho HD. 3DIP does not have the intention or purpose to engage in any conduct which constricts the continuing and stable implementation of business of Toho HD and/or Toho HD group companies.

This press release may include Third-Party Materials. Permission to quote from Third-Party Materials in this press release may neither have been sought nor obtained. The content of the Third-Party Materials has not been independently verified by 3DIP and does not necessarily represent the views of 3DIP. The authors and/or publishers of the Third-Party Materials are independent of, and may have different views to 3DIP. Quoting Third-Party Materials in this press release does not imply that 3DIP endorses or concurs with any part of the content of the Third-Party Materials or that any of the authors or publishers of the Third-Party Materials endorses or concurs with any views which have been expressed by 3DIP on the relevant subject matter. The Third-Party Materials may not be representative of all relevant news coverage or views expressed by other third parties on the stated issues.

In respect of information that has been prepared by 3DIP (and not otherwise attributed to any other party) and which appears in the English language version of this press release, in the event of any inconsistency between the English language version and the Japanese language version of this press release, the meaning of the Japanese language version shall prevail unless otherwise expressly indicated.

Contacts

KRIK (PR Agent)

Koshida: +81-70-8793-3990

Sugiyama: +81-70-8793-3989

World-Leading Cancer Center, The Royal Marsden NHS Foundation Trust, Using AI to Push Boundaries of Cancer Research With NTT DATA and CARPL.ai




World-Leading Cancer Center, The Royal Marsden NHS Foundation Trust, Using AI to Push Boundaries of Cancer Research With NTT DATA and CARPL.ai

• This partnership launches a large-scale, AI-powered service designed to accelerate cancer detection and treatment using medical imaging in the UK’s National Health Service (NHS)
• The Royal Marsden NHS Foundation Trust is ranked among world’s top cancer research centers
• Marks a milestone in the application of artificial intelligence for cancer research and clinical innovation

LONDON–(BUSINESS WIRE)–The Royal Marsden NHS Foundation Trust, a world-leading specialist cancer center, has today announced a pioneering partnership with NTT DATA, a global leader in digital business and technology services, and CARPL.ai, a leading enterprise imaging artificial intelligence (AI) and machine learning operations (MLOps) platform. Together, they have designed and built an advanced AI-powered radiology analysis service for the development and evaluation of AI in medical imaging, designed to transform cancer research and, ultimately, improve patient outcomes.

AI’s potential to enhance the speed and accuracy of identifying imaging biomarkers has long been recognized. Funded by a three-year grant from the UK’s National Institute for Health and Care Research (NIHR), the service will be used for research at The Royal Marsden and the Institute of Cancer Research (ICR), including projects in collaboration with other research teams. This research initiative will focus on developing and evaluating AI algorithms to improve the accuracy of cancer evaluation, including sarcoma, lung, breast, brain and prostate cancers. This will lead to faster response times, more accurate diagnoses and better-targeted treatments.

The service runs on a MLOps clinical imaging platform, built and operated by NTT DATA. To enable this, NTT DATA developed a bespoke AI computing solution leveraging high-performance Dell servers and utilizing the latest GPU processing capacity orchestrated by the CARPL.ai platform, which helps test and manage AI algorithms and includes a large collection of radiology AI models.

NTT DATA is also providing specialist imaging AI consulting services, helping researchers at The Royal Marsden test and evaluate emerging AI tools in real clinical settings, while extracting maximum insight and value from both in-house and commercial algorithms.

“AI has immense potential to support clinicians in diagnosing and treating cancer earlier and more precisely,” said Professor Dow-Mu Koh, Professor in Functional Cancer Imaging and Consultant Radiologist in Functional Imaging at The Royal Marsden. “By working with NTT DATA and CARPL.ai, we’ve created a scalable research environment that allows us to explore the full potential of AI safely and in a way that could one day transform cancer diagnosis and treatment across the NHS.”

Minister of State for Health, Karin Smyth, said: “Our 10 Year Health Plan will modernize the NHS, replacing outdated systems with cutting-edge digital solutions. While this trial is in its early stages, it represents exactly the kind of collaboration between the NHS, industry and academia that will help build a health service fit for the future. Early detection saves lives, and innovations like AI will transform how cancer is diagnosed and treated – helping patients receive faster and more effective care.”

Professor Mike Lewis, NIHR Scientific Director for Innovation, said: “Cancer is one of the biggest killers in the UK. That must change. This three-year grant will help researchers push the boundaries of AI-driven technology for cancer detection and diagnosis.

“This AI-powered service represents the cutting edge of cancer research and it is going to transform treatment, better support NHS staff and ultimately change patients’ lives. It is another great example of how NIHR-funded and supported research will ensure the best care is there when patients need it.”

Tom Winstanley, Chief Technology Officer at NTT DATA UK & Ireland, commented: “This service is a great example of responsible innovation in practice, showing the ethical, secure use of AI in healthcare. We are very proud to support The Royal Marsden in pushing the boundaries of cancer research.”

Once the service is live, research teams at The Royal Marsden will be able to evaluate a range of AI models across several cancer types. These studies will generate critical insights into how AI can support clinical decision-making and shape future approaches to diagnosis and treatment. Through CARPL.ai’s centralized interface and built-in monitoring tools, the research teams will also be able to track model performance over time, enabling faster feedback loops between development and deployment – a crucial step towards clinical translation. NTT DATA will continue to work closely with The Royal Marsden to support this next phase of research which will ultimately improve cancer care and patient outcomes.

About NTT DATA

NTT DATA is a $30+ billion trusted global innovator of business and technology services. We serve 75% of the Fortune Global 100 and are committed to helping clients innovate, optimize and transform for long-term success. As a Global Top Employer, we have experts in more than 50 countries and a robust partner ecosystem of established and start-up companies. Our services include business and technology consulting, data and artificial intelligence, and industry solutions, as well as the development, implementation and management of applications, infrastructure and connectivity. We are also one of the world’s leading providers of digital and AI infrastructure. NTT DATA is part of NTT Group, which invests over $3.6 billion each year in R&D to help organizations and society move confidently and sustainably into the digital future.

Visit us at https://uk.nttdata.com/

About The Royal Marsden NHS Foundation Trust

The Royal Marsden opened in 1851 as the world’s first hospital dedicated to cancer diagnosis, treatment, research and education. Today it operates as a specialist cancer center and the Trust was delighted to welcome Her Royal Highness The Princess of Wales, who became Joint Patron with His Royal Highness The Prince of Wales, in January this year.

Together with its principal academic partner, The Institute of Cancer Research (ICR), The Royal Marsden is designated as the UK’s only National Institute for Health and Care Research (NIHR) Biomedical Research Centre (BRC) dedicated solely to cancer.

The Royal Marsden and the ICR are recognized as one of the top four comprehensive cancer centers in the world for the impact of their research, influencing cancer treatment and care for all cancer patients. It is a center of excellence, pioneering the very latest in cancer treatments and technologies, as well as leading the way in innovative cancer diagnosis and education.

The Royal Marsden operates from three centers, in Chelsea, Sutton and Cavendish Square in central London. It also has a Medical Day Unit in Kingston, and is the founder and host of RM Partners West London Cancer Alliance, which includes St George’s University Hospitals NHS Foundation Trust, Imperial Healthcare NHS Trust, and other healthcare partners across north west and south west London.

Driven by the fundamental principle that patients, entrusting their lives to The Royal Marsden, deserve the very best, The Royal Marsden is committed to delivering excellent research‑led cancer care for patients, accelerating early diagnosis, and ensuring treatment and care is personalized for the needs of each individual.

Contacts

Hotwire Global

nttdata@hotwireglobal.com

Innate Pharma Announces Its Participation in Jefferies and Goldman Sachs Healthcare Conferences




Innate Pharma Announces Its Participation in Jefferies and Goldman Sachs Healthcare Conferences

MARSEILLE, France–(BUSINESS WIRE)–#IRConferences–Regulatory News:

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that members of its executive team will present and host 1×1 meetings at the upcoming investor conferences, detailed below.

• Jefferies Global Healthcare Conference
  
  Dates: June 3 – 5 2025 | New York, USA

The executive team will participate in a fireside chat scheduled on Thursday, June 5, 2025, from 7:35 to 8:05 am EDT.

• Goldman Sachs 46^th Annual Global Healthcare Conference
  
  Dates: June 9 – 11 2025 | Miami, USA

The executive team will participate in a fireside chat scheduled on Tuesday, June 10, 2025, from 4:00 to 4:35 pm EDT.

In addition, members of the executive team will participate and represent the Company during the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting being held from May 30 to June 3, 2025 in Chicago, Illinois.

About Innate Pharma

Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through three therapeutic approaches: multi-specific NK Cell Engagers via its ANKET^® (Antibody-based NK cell Engager Therapeutics) proprietary platform and Antibody Drug Conjugates (ADC) and monoclonal antibodies (mAbs).

Innate’s portfolio includes several ANKET^® drug candidates to address multiple tumor types as well as IPH4502, a differentiated ADC in development in solid tumors. In addition, anti-KIR3DL2 mAb lacutamab is developed in advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas, and anti-NKG2A mAb monalizumab is developed with AstraZeneca in non-small cell lung cancer.

Innate Pharma is a trusted partner to biopharmaceutical companies such as Sanofi and AstraZeneca, as well as leading research institutions, to accelerate innovation, research and development for the benefit of patients.

Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.

Learn more about Innate Pharma at www.innate-pharma.com and follow us on LinkedIn and X.

Information about Innate Pharma shares

Disclaimer on forward-looking information and risk factors

This press release contains certain forward-looking statements, including those within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. The use of certain words, including “anticipate,” “believe,” “can,” “could,” “estimate,” “expect,” “may,” “might,” “potential,” “intend,” “should,” “will,” or the negative of these and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company’s reliance on third parties to manufacture its product candidates, the Company’s commercialization efforts and the Company’s continued ability to raise capital to fund its development. For an additional discussion of risks and uncertainties, which could cause the Company’s actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque”) section of the Universal Registration Document filed with the French Financial Markets Authority (“AMF”), which is available on the AMF website http://www.amf-france.org or on Innate Pharma’s website, and public filings and reports filed with the U.S. Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 20-F for the year ended December 31, 2024, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company. References to the Company’s website and the AMF website are included for information only and the content contained therein, or that can be accessed through them, are not incorporated by reference into, and do not constitute a part of, this press release.

In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by the Company or any other person that the Company will achieve its objectives and plans in any specified time frame or at all. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

Contacts

For additional information, please contact:

Investors
Innate Pharma
Henry Wheeler

Tel.: +33 (0)4 84 90 32 88

Henry.wheeler@innate-pharma.fr

Media Relations
NewCap
Arthur Rouillé

Tel.: +33 (0)1 44 71 00 15

innate@newcap.eu

Quadria Capital Closes Oversubscribed US$1 Billion Fund III to Advance Healthcare Transformation Across Asia




Quadria Capital Closes Oversubscribed US$1 Billion Fund III to Advance Healthcare Transformation Across Asia

• Fund close exceeds initial target despite a challenging fundraising environment, reflecting strong investor confidence in India and Southeast Asia healthcare
• Existing investors increased commitment amount by an average of 80%
• New capital raised from blue-chip global institutions, alongside a significant rise in Asian investor participation

SINGAPORE–(BUSINESS WIRE)–Quadria Capital, Asia’s premier healthcare-focused private equity firm, today announced the final close of its Fund III with US$1.07 billion in total commitments, significantly exceeding its original $800 million target.

The oversubscribed fundraise comprises over US$954 million in primary commitments and US$114 million in committed co-investment capital. An additional US$300 million co-investment capacity is anticipated over the course of the investment phase, bringing total committed capital to approximately US$1.3 billion upon full deployment.

This latest fundraise is around 60% larger than the firm’s previous $600m fund raised in 2020, cementing Quadria’s position as the largest dedicated healthcare private equity fund in South and Southeast Asia.

“Fund III’s close, amid one of the most demanding fundraising climates in recent memory, is a powerful validation of our strategy and our mission,” said Abrar Mir, Co-Founder and Managing Partner, Quadria Capital. “It reflects deep global investor conviction in the transformational opportunity in Asian Healthcare, where social impact and financial performance go hand in hand.”

Global Institutional Backing Across Continents

At a time when global capital is cautious, Quadria’s ability to consistently attract top-tier global investors underscores the strong conviction in its investment strategy and the undeniable opportunities in the Asian healthcare market.

Quadria Capital’s largest existing backers include prominent North American and European sovereign wealth funds, asset managers, and strategic corporates. The Fund also secured new commitments from globally recognized institutional investors. Most notably, there was strong backing from leading institutions across the GCC, including Saudi Arabia, the UAE, and Bahrain. The fundraise further attracted interest from India, with fresh capital from major banks, insurance companies, and family offices. Additionally, the Fund received robust re-up commitments from impact investors – underscoring Quadria’s continued dedication to scalable, high-impact healthcare businesses that deliver lifesaving care to underserved populations across Asia.

Positioned for Structural Growth in Asia’s $5 Trillion Healthcare Market

“With Asia expected to drive 40% of global healthcare growth by 2030¹, Fund III positions Quadria to lead a new era of private capital-driven healthcare transformation across the region,” Abrar Mir added.

“Asia’s healthcare sector is at a pivotal moment, and it will remain in the limelight in 2025, especially with investment interest in India in areas like single-specialty hospitals, diagnostic chains, medical devices, and pharmaceutical manufacturing, which includes APIs and CDMOs. This sector will see growth because of higher healthcare consumption, cost-efficiency initiatives, and deepening technology integration. We are entering a golden decade of healthcare transformation,” said Dr Amit Varma, Co-Founder and Managing Partner, Quadria Capital.

Fund III will build a diversified portfolio of approximately 10 market-leading companies, taking both significant minority and majority stakes, and further scaling impact through targeted co-investments from Limited Partners (LPs).

Already nearly 40% deployed – including closed and signed investments – the fund has invested in Aragen Life Sciences (a global CRDMO serving over 400 pharma clients), NephroPlus (Asia’s largest dialysis chain), and Maxivision (India’s leading eye care chain). Two new investments in Southeast Asia are expected soon. Fund III builds on Quadria Capital’s track record of successful exits from Funds I and II, underscoring the strength of its investment strategy, operational expertise and ability to distribute capital back to investors.

About Quadria:

Founded in 2012, Quadria Capital is Asia’s premier healthcare investor managing over US$4 billion in assets across 27 investments in South and Southeast Asia including India, Vietnam, Indonesia, Malaysia and Singapore. Quadria Capital aims to create significant and sustainable shareholder value by partnering with exceptional healthcare businesses to enhance their impact and scale, while generating superior returns for investors.

For more information, please visit www.quadriacapital.com

¹ https://www.bcg.com/publications/2025/india-the-unmissable-asia-healthcare-opportunity

Contacts

Media Contact:
Yvette Lim

Yvette.lim@fgsglobal.com

Eurofins Scientific SE: Director/PDMR Shareholding




Eurofins Scientific SE: Director/PDMR Shareholding

LUXEMBOURG–(BUSINESS WIRE)–Eurofins Scientific SE (EUFI.PA) has received various notifications of dealing from Persons Discharging Managerial Responsibilities (“PDMR”). The notification of Dealing Form for each PDMR can be found below.

This notification is made in accordance with the European Market Abuse Regulation.

About Eurofins – the global leader in bio-analysis

Eurofins is Testing for Life. With ca. 63,000 staff across a network of more than 950 laboratories in over 1,000 companies in 60 countries, Eurofins offers a portfolio of over 200,000 analytical methods.

Eurofins Scientific S.E. shares are listed on Euronext Paris Stock Exchange.

Contacts

For more information, please visit www.eurofins.com or contact:

Investor Relations

Eurofins Scientific SE

Phone: +32 2 766 1620

E-mail: ir@sc.eurofinseu.com

GLP-1R Agonists: Pioneering in Metabolic, Neurologic, and Cardiologic Markets – ResearchAndMarkets.com




GLP-1R Agonists: Pioneering in Metabolic, Neurologic, and Cardiologic Markets – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “GLP-1R Agonists – Label Extensions/Drug Repurposing: Market Overview” report has been added to ResearchAndMarkets.com’s offering.

This report is a market overview of GLP-1R agonists, focusing on their potential repurposing and label expansions in diseases outside type 2 diabetes and obesity.

The potential of GLP-1RAs is based on their insulin sensitization and anti-inflammatory properties.

GLP-1RAs are being investigated in different diseases in the metabolic, neurologic, and cardiologic markets.

Novo Nordisk and Eli Lilly are currently the major players in the GLP-1RA space, but opportunity remains for new entrants.

Report Scope

• Overview of GLP-1R agonists, including marketed GLP-1RAs and diseases under investigation.
• Analysis of unmet needs, challenges and opportunities in GLP-1RAs repurposing.
• Pipeline analysis and opportunity assessment of GLP-1RAs in different therapeutic areas.
• Overview of current major players in the GLP-1RAs space and potential future players.
• GLP-1RAs global market outlook and deals overview.

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the GLP-1RAs therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the GLP-1RAs therapeutics market in the future.
• Identify the major challenges and opportunities in the GLP-1RA space and the potential of this therapeutic class in multiple indications.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Key Topics Covered:

1 Preface

2 Executive Summary

3 GLP-1R Agonists Overview

3.1 What Are GLP-1R Agonists

3.2 GLP-1R in the Body

3.3 History of GLP-1R Agonists

4 Industry Trends

4.1 Oral GLP-1Ras

4.2 Lower Dosing Frequency

4.3 Combination and Dual/Triple Agonists

4.4 Repurposing GLP-1Ras

5 Marketed Products

5.1 Global GLP-1RA Marketed Landscape

5.2 Marketed GLP-1Ras

5.3 Challenges and Opportunities in GLP-1RA Repurposing

5.4 Key Opinion Leader Perspectives on GLP-1RA Unmet Needs

6 Pricing and Reimbursement Assessment Case Study: Ozempic

7 Pipeline Analysis

7.1 Top 20 Indications with GLP-1RAs in Development

7.2 Top Five Therapeutic Areas with the Most GLP-1RA Pipeline Assets

7.3 GLP-1RA Pipeline Candidates

7.4 Where Are GLP-1RAs Expected to Position in the Future Chronic Kidney Disease Treatment Landscape?

7.5 Where Are GLP-1RAs Expected to Position in the Future Heart Failure Treatment Landscape?

7.6 Key Opinion Leader Perspectives on GLP-1RAs in the Treatment for Heart Failure and Chronic Kidney Disease

7.7 GLP-1RA Opportunities Beyond Planned Label Expansions

7.8 Key Opinion Leader Perspectives on GLP-1RAs in the Treatment of Polycystic Ovary Syndrome

8 Opportunities and Challenges

8.1 Opportunities: the Role of GLP-1RAs in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis

8.2 Opportunities: GLP-1RAs in Liver Diseases

8.3 Key Opinion Leader Perspectives on GLP-1RAs in the Treatment of Liver Diseases

8.4 Opportunities: the Role of GLP-1RAs in Neurodegenerative Diseases

8.5 Opportunities: GLP-1RAs in Central Nervous System Disorders

8.6 Key Opinion Leader Perspectives on GLP-1RAs in the Treatment of Parkinson’s Disease

8.7 Opportunities: the Role of GLP-1RAs in Diastolic Heart Failure and Stroke

8.8 Opportunities: GLP-1RAs in Cardiovascular Diseases

8.9 Opportunities: the Role of GLP-1RAs in Chronic Kidney Disease

8.10 Opportunities: GLP-1RAs in Other Diseases

9 Companies

9.1 Current Major Player: Novo Nordisk

9.2 Current Major Player: Eli Lilly

9.3 Potential Future Players

9.4 Key Opinion Leader Perspectives on Future Players in the GLP-1RA Space

10 Market Outlook and Deals

10.1 GLP-1RA Global Market

10.2 Top 20 Major Deals and Acquisitions Between 2022 and 2025 with GLP-1Ras

Company Coverage Includes:

• Novo Nordisk AS
• Eli Lilly and Co
• Shanghai Minwei Biotechnology Co Ltd
• Metsera Inc
• Sihuan Pharmaceutical Holdings Group Ltd
• Hanmi Pharmaceuticals Co Ltd
• Jiangsu Hengrui Medicine Co Ltd
• AstraZeneca Plc
• PegBio Co Ltd
• Beijing QL Biopharmaceutical Co Ltd
• Sciwind Biosciences Co Ltd
• U.S. National Institutes of Health
• Boehringer Ingelheim International GmbH
• i2O Therapeutics Inc
• Zhejiang Doer Biologics Corp
• CSPC Pharmaceutical Group Ltd
• Peptron Inc
• Carmot Therapeutics Inc
• Amogen Pharma Pvt Ltd
• BioLingus AG
• The United Laboratories International Holdings Ltd
• Tonghua Dongbao Pharmaceutical Co Ltd
• Annovis Bio Inc
• ImmunoForge Co Ltd
• Biogenomics Ltd
• China Pharmaceutical University
• Zhejiang Heze Pharmaceutical Technology Co Ltd
• Zhuhai United Laboratories Co Ltd
• Hangzhou Jiuyuan Gene Engineering Co Ltd
• Structure Therapeutics Inc
• Altimmune Inc
• Chia Tai Tianqing Pharmaceutical Group Co Ltd
• Gmax Biopharm LLC
• Guangzhou Dazhou Biomedical Technology Co Ltd
• Hangzhou Zhongmei Huadong Pharmaceutical Co Ltd
• Huadong Medicine Co Ltd
• Innovent Biologics Inc
• Merck & Co Inc
• Neuraly Inc
• Onegene Biotechnology Inc
• Protheragen Inc
• RenaissThera Pvt Ltd
• Sekkei Inc
• Uni-Bio Science Group Ltd
• HEC Pharma Co Ltd
• Jiangsu Hansoh Pharmaceutical Group Co Ltd
• Cascade Pharmaceuticals Inc
• D&D Pharmatech Co Ltd
• Huons Global Co Ltd
• Immunwork Inc
• Leto Laboratories Co Ltd
• MetaVia Inc
• Pfizer Inc
• Qilu Regor Therapeutics Inc
• Sanofi
• Xintrum Pharmaceuticals Ltd
• Gan & Lee Pharmaceuticals Co Ltd
• Adocia SAS
• AnyGen Co Ltd
• Ascendis Pharma AS
• AULBIO Co Ltd
• BrightGene Bio-Medical Technology Co Ltd
• Camurus AB
• HK inno.N Corp
• Hybio Pharmaceutical Co Ltd
• IGC Pharma Inc
• Lancaster University
• Laxxon Medical GmbH
• Poolbeg Pharma Plc
• ProGen Co Ltd
• Septerna Inc
• Shanghai Innogen Pharmaceutical Technology Co Ltd
• Shenzhen Salubris Pharmaceuticals Co Ltd
• Sun Pharmaceutical Industries Ltd
• Suzhou Wingtech Pharmaceutical Technology Co Ltd
• Theertha Biopharma Pvt Ltd
• Verdiva Bio Ltd
• Vivani Medical Inc
• Yunovia Co Ltd
• Adare Pharma Solutions
• Amgen Inc
• Apeloa Pharmaceutical Co Ltd
• ApicHope Pharmaceutical Co Ltd
• Arecor Therapeutics Plc
• Biolexis Therapeutics Inc
• Biomea Fusion Inc
• Biomed Industries Inc
• BioNxt Solutions Inc
• California Institute for Biomedical Research
• China Medical System Holdings Ltd
• Chongqing Chenan BioPharm Co Ltd
• CinFina Pharma LLC
• Crinetics Pharmaceuticals Inc
• CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co Ltd
• Daewoong Therapeutics Inc
• Diabetology (Products) Ltd
• Dx&Vx
• Efil Bioscience Inc
• Entera Bio Ltd
• Gilead Sciences Inc
• Guangzhou BeBetter Medicine Technology Co Ltd
• HangZhou HuiSheng Biotech Pharmaceutical Co Ltd
• Hepagene Therapeutics Inc
• HighField Biopharmaceuticals, Inc.
• Hua Medicine Shanghai Ltd
• INVENT Pharmaceuticals Inc
• Inventage Lab Inc
• iX Biopharma Ltd
• Jiangsu Normal University
• Jiangsu Sinopep Allsino Biopharmaceutical Co Ltd
• Livzon Pharmaceutical Group Inc
• MeiraGTx Holdings Plc
• MindRank Ltd
• Niedlfree Technologies Pvt Ltd
• OPKO Health Inc
• Remedium Bio Inc
• Scohia Pharma Inc
• Shandong New Era Pharmaceutical Co Ltd
• SN BioScience Co Ltd
• Tharimmune Inc
• Viking Therapeutics Inc
• vTv Therapeutics Inc
• Youngene Therapeutics Co Ltd
• Zealand Pharma AS
• 4Moving Biotech
• Abaxys Therapeutics SA
• Aerami Therapeutics Holdings Inc
• AI Proteins Inc
• Akrikhin
• Alphamab Oncology
• Aprilbio Co Ltd
• Ascletis Pharma Inc
• Beijing Eastern Biotech Co Ltd
• Beijing SL Pharmaceutical Co Ltd
• Biora Therapeutics Inc
• Bostal Drug Delivery Co Ltd
• Bristol-Myers Squibb Co
• Chengdu Brilliant Pharmaceutical Co Ltd
• China Resources Double-Crane Pharmaceutical Co Ltd
• Closed Loop Medicine Ltd
• Coya Therapeutics Inc
• Delpor Inc
• Duke University
• Enteris BioPharma Inc
• G2GBIO Inc
• GlyTech Inc
• Gubra ApS
• Halo Therapeutics Ltd
• HEC Pharm Group
• Hualan Biological Engineering Inc
• Iconovo AB
• Icure Pharmaceutical Inc
• Imagine Pharma LLC
• Immupharma Plc
• Imperial College London
• Innopharmax Inc
• Jiangsu Wanbang Biochemical Pharmaceutical Group Co Ltd
• Kailera Therapeutics Inc
• Kariya Pharmaceuticals IVS
• Kunming Yinnuo Medical Technology Co. Ltd.
• Lanzhou Institute of Biological Products Co Ltd
• Lepu Medical Technology (Beijing) Co Ltd
• Mapi Pharma Ltd
• MBX Biosciences Inc
• Metaphore Biotechnologies Inc
• Nanexa AB
• National Institute of Biomedical Imaging and Bioengineering
• NutriBand Inc
• Oramed Pharmaceuticals Inc
• Original BioMedicals Co Ltd
• Pep2Tango Therapeutics Inc
• ProLynx LLC
• Qilu Pharmaceutical Co Ltd
• QuiaPEG Pharmaceuticals AB
• Rani Therapeutics LLC
• Rivus Pharmaceuticals Inc
• Rose Pharma Inc
• R-Pharm
• Sail Biomedicines Inc
• Shandong Boan Biotechnology Co Ltd
• Shanghai Fosun Pharmaceutical (Group) Co Ltd
• Sino Biopharmaceutical Ltd
• Syracuse University
• Terns Pharmaceuticals Inc
• Terry Suzhou Pharmaceutical Co Ltd
• The University of Adelaide
• Twist Bioscience Corp
• University of Padova
• University of Ulster
• Vanderbilt University
• Virtici LLC
• Wuxi Hebang Biotechnology Co Ltd
• Yichang Humanwell Pharmaceutical Co Ltd
• Yonsei University College of Medicine
• Zhejiang HuaYang Pharmaceutical Co Ltd
• Zhongshan Wanhan Pharmaceutical Co Ltd

For more information about this report visit https://www.researchandmarkets.com/r/vp1h5m

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Biologics CDMO Global and Regional Market Analysis Report 2025-2035: Outsourcing Trend Accelerates as Biologics CDMOs Offer Speed, Scale, and Regulatory Expertise – ResearchAndMarkets.com




Biologics CDMO Global and Regional Market Analysis Report 2025-2035: Outsourcing Trend Accelerates as Biologics CDMOs Offer Speed, Scale, and Regulatory Expertise – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Biologics CDMO Market – A Global and Regional Analysis: Focus on Cell Type, Indication, Molecule Type, and Region – Analysis and Forecast, 2025-2035” report has been added to ResearchAndMarkets.com’s offering.

The biologics CDMO market is undergoing rapid expansion, solidifying its role as a crucial component of the biopharmaceutical industry. This dynamic sector is driven by the increasing demand for outsourcing services in the development and manufacturing of biologic drugs. Biologics, including monoclonal antibodies, recombinant proteins, and gene therapies, constitute a rapidly growing segment within the pharmaceutical landscape.

As pharmaceutical and biotech companies strive to bring innovative biologics to market, they increasingly rely on biologics CDMO providers for specialized expertise, cutting-edge technologies, and cost-efficient solutions. The market is characterized by a diverse range of biologics CDMO players, each offering unique capabilities across the entire biologics development and manufacturing value chain.

The global biologics CDMO market is experiencing rapid growth, driven by the increasing demand for biologic therapies and the growing trend of outsourcing development and manufacturing processes. Pharmaceutical companies are increasingly relying on biologics CDMOs to handle the complexities of biologic drug production, which requires specialized expertise, advanced infrastructure, and stringent regulatory compliance. By outsourcing to biologics CDMOs, companies can streamline operations, reduce costs, and accelerate time-to-market, allowing them to focus more on their core competencies in research and development.

The biologics CDMO market in the Asia-Pacific (APAC) region is experiencing rapid growth, driven by increasing demand for biopharmaceuticals, technological advancements, and the rising burden of chronic diseases. Among APAC countries, China is leading the market, fueled by strong government support, a growing biosimilars industry, and an expanding biomanufacturing infrastructure. The country’s strategic investments in biologics production, coupled with evolving regulatory frameworks that favor contract biomanufacturing, have positioned China as a key hub for biologics CDMO services in the region.

Several factors are fueling the expansion of the biologics CDMO market, including the rising prevalence of chronic diseases such as cancer, diabetes, and autoimmune disorders, which drive the need for innovative biologic treatments. Additionally, advancements in biotechnology are enabling the development of next-generation biologics, including monoclonal antibodies, cell and gene therapies, and recombinant proteins. The aging global population is further increasing the demand for these therapies, prompting pharmaceutical companies to seek flexible and scalable manufacturing solutions. As a result, the biologics CDMO market is expected to continue its strong growth trajectory, playing a crucial role in the evolving pharmaceutical landscape.

The biologics CDMO market is well-positioned for continued growth as pharmaceutical companies increasingly turn to biologics CDMOs to accelerate the development and commercialization of biologic therapies. Biologics CDMOs offer a comprehensive range of services, including upstream processing, downstream processing, and analytical services, enabling pharmaceutical companies to bring their biologics products to market more quickly and efficiently. As the demand for biologics continues to rise, biologics CDMOs are playing a crucial role in optimizing production and ensuring high-quality manufacturing.

The biologics CDMO market is also benefiting from significant investments in expanding CDMO capacity to meet the increasing demand for biologics manufacturing services. To stay competitive and enhance operational efficiency, biologics CDMOs are adopting advanced technologies such as single-use bioreactors and continuous manufacturing. These innovations help improve scalability, reduce costs, and enhance flexibility in biologics production. With continuous advancements and increasing reliance on outsourced services, the biologics CDMO market is poised for sustained growth in the coming years.

With a global footprint, biologics CDMO providers are well-equipped to meet the industry’s growing demand for flexible, high-quality, and efficient solutions in biologics development and manufacturing. As the biopharmaceutical market continues to expand, the biologics CDMO market is set to play a pivotal role in accelerating the transition of innovative therapies from concept to commercialization. By leveraging advanced technologies, regulatory expertise, and scalable production capabilities, biologics CDMO firms are becoming indispensable partners in the evolving biopharmaceutical landscape.

Mammalian Segment to Dominate the Global Biologics CDMO Market (by Cell Type)

The mammalian segment dominated the global biologics CDMO market (by cell type) in FY2024, driven by its ability to accurately replicate complex proteins with high bioactivity and minimal post-translational modifications. Widely preferred for biopharmaceutical production, mammalian cell lines are particularly suited for manufacturing monoclonal antibodies, which constitute a significant share of biologic drugs.

Offering scalability, robust performance, and compatibility with the intricate demands of therapeutic protein production, mammalian cell cultures play a crucial role in advancing biomanufacturing. As the biologics CDMO market continues to grow, the prominence of mammalian cell culture technology underscores its importance in meeting the global demand for cutting-edge biopharmaceuticals.

Oncology Segment to Dominate the Global Biologics CDMO Market (by Indication)

The oncology segment led the global biologics CDMO market (by indication) in FY2024, driven by the surge in cancer research and the development of targeted therapies and immunotherapies. A significant portion of biopharmaceutical innovations is focused on oncology, leading biologics CDMOs to increasingly specialize in manufacturing monoclonal antibodies, cell-based therapies, and other cancer-targeting biologics.

This trend underscores the growing emphasis on personalized medicine and the need for advanced manufacturing capabilities to address the complexities of oncology treatments, reinforcing the pivotal role of biologics CDMOs in supporting the evolving landscape of cancer therapeutics.

Monoclonal Antibodies Segment to Dominate the Global Biologics CDMO Market (by Molecule Type)

The monoclonal antibodies (mAbs) segment dominated the global biologics CDMO market (by molecule type) in FY2024, driven by their widespread adoption in treating cancer, autoimmune disorders, and infectious diseases.

As precision medicine continues to gain momentum, mAbs offer highly targeted and specific therapeutic approaches, further increasing their demand. This surge has led biologics CDMOs to experience growing requests for the development and manufacturing of monoclonal antibodies, reinforcing their critical role in the evolving landscape of biologic drug development and advanced therapeutics.

Key Market Players

• AbbVie Inc.
• AGC Biologics
• Binex Co. Limited
• Boehringer Ingelheim International GmbH
• Catalent, Inc
• Lonza
• Novartis AG
• Parexel International Corporation
• Samsung Biologics
• Toyobo Co., Ltd.
• WuXi Bio
• Catalent
• Fujifilm Diosynth

Key Topics Covered:

Executive Summary

Scope of the Study

Research Methodology

1. Global Biologics CDMO Market Overview

1.1 Market Outlook

1.1.1 Definitions

1.1.2 Inclusion and Exclusion Criteria

1.1.3 Market Size, 2024 – 2035 (US$)

1.1.4 Market Growth Scenario

1.1.4.1 Realistic Scenario

1.1.4.2 Optimistic Scenario

1.1.4.3 Pessimistic Scenario

1.2 Industry Outlook

1.2.1 Introduction

1.2.2 Market Overview and Ecosystem

1.2.3 Key Trends

1.2.4 Market Footprint

1.2.5 Patent Analysis

1.2.6 Factors Considered while Outsourcing to CDMO

1.2.7 Regulatory Landscape / Compliances

1.3 Market Dynamics

1.3.1 Market Opportunities and Trends

1.3.2 Market Drivers

1.3.2.1 Impact Analysis

1.3.3 Market Restraints

1.3.3.1 Impact Analysis

2. Global Biologics CDMO Market Analysis (By Cell Type), $ Million, 2024-2035

2.1 Cell Type Summary

2.2 Mammalian

2.3 Microbial

2.4 Others

3. Global Biologics CDMO Market Analysis (By Indication), $ Million, 2024-2035

3.1 Indication Summary

3.2 Oncology

3.3 Auto-Immune Diseases

3.4 Infectious Diseases

3.5 Neurology

3.6 Others

4. Global Biologics CDMO Market Analysis (By Molecule Type), $ Million, 2024-2035

4.1 Molecule Type Summary

4.2 Monoclonal Antibodies

4.3 Recombinant Proteins

4.4 Vaccines

4.5 Hormones

4.6 Others

5. Global Biologics CDMO Market Analysis (By Region), $ Million, 2024-2035

5.1 Regional Summary

5.2 Drivers and Restraints

5.2.1 North America

5.2.1.1 By Cell Type

5.2.1.2 By Molecule Type

5.2.1.2.1 North America (by Country)

5.2.1.2.1.1 U.S

5.2.1.2.1.1.1 By Cell Type.

5.2.1.2.1.1.2 By Molecule Type

5.2.1.2.1.2 Canada

5.2.1.2.1.2.1 By Cell Type.

5.2.1.2.1.2.2 By Molecule Type

5.2.2 Europe

5.2.3 Asia-Pacific

5.2.4 Latin America

5.2.5 Middle East & Africa

6. Global Biologics CDMO Market – Competitive Benchmarking and Company Profiles

6.1 Competitive Benchmarking

6.2 Competitive Landscape

6.2.1 Key Strategies and Developments by Company

6.2.1.1 Funding Activities

6.2.1.2 Mergers and Acquisitions

6.2.1.3 Regulatory Approvals

6.2.1.4 Partnerships, Collaborations, and Business Expansions

6.2.2 Key Developments Analysis

6.2.3 Company Share Analysis/ Company Position Analysis, 2023- 2023

6.3 Company Profiles

For more information about this report visit https://www.researchandmarkets.com/r/on9iw0

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900